Mesoblast Limited (ASX:MSB) Completes Enrolment For First Spinal Fusion Trial

Melbourne, April 30, 2010 AEST (ABN Newswire) - Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (ADR:MBLTY),today announced it had cash reserves of $12.6 million for the reporting period ended 31 March 2010. The results are in line with expectations and reflect prudent cash management and tight control of resources.

During the current quarter, Mesoblast and its United States-based associate company, Angioblast Systems, have continued to make strong progress in their respective clinical programs for spinal fusion, heart failure, and bone marrow transplantation.

Mesoblast's first trial evaluating its proprietary allogeneic, or "off-the-shelf", stem cells for posterolateral lumbar spinal fusion, at New York's Hospital for Special Surgery, has now completed enrolment, and has been fully reviewed by the Data Safety and Monitoring Board. This trial compared the safety and efficacy of Mesoblast's NeoFuse(TM) allogeneic stem cell product on one side with the standard-of-care, autograft bone, on the other side in the same patient.

The results showed that implantation of the cells was safe and was associated with earlier generation of new bone formation and fusion which was robust, as determined by CT scan. Patients continue to be followed and to date no cell-related adverse events have occurred. At 6 months of follow-up, 3/5 sites (60%) that received the lowest dose tested of NeoFuse(TM) demonstrated fusion, as determined by bone bridging between two vertebrae whereas only 1/7 sites (14%) which received autograft demonstrated fusion.

These initial results are very encouraging, and support prior preclinical data which have shown that Mesoblast's allogeneic cells generate faster fusion in the lumbar and cervical spine than the autograft standard-of-care.

Mesoblast's current Phase 2 trial for minimally-invasive posterior lumbar interbody fusion is fully funded and continues to recruit rapidly. The results from this second trial will form the basis for pivotal trial design in support of Mesoblast's activities to commercialise a lumbar spinal fusion product.

Contact

Julie Meldrum Corporate Communications Director Mesoblast Limited Tel: +61-3-9639-6036 Mob: +61-419-228-128 Email: julie.meldrum@mesoblast.com www.mesoblast.com